Compare EFR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFR | PBYI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.1M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | EFR | PBYI |
|---|---|---|
| Price | $11.07 | $5.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 88.6K | ★ 396.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.43% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 1.69 | 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $7.74 | $7.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $2.58 |
| 52 Week High | $13.29 | $6.12 |
| Indicator | EFR | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 65.69 |
| Support Level | $11.14 | $5.51 |
| Resistance Level | $11.24 | $5.73 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 26.09 | 94.70 |
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.